Related Experiment Video
Updated: Sep 21, 2025
06:35
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
7.3K
Looking ahead: giant-cell arteritis in 10 years time.
Milena Bond1, Alessandro Tomelleri2, Frank Buttgereit3
1Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy.
Therapeutic Advances in Musculoskeletal Disease
|May 31, 2022
Summary
Giant-cell arteritis (GCA) diagnosis and treatment have improved, but research is needed. Future studies will focus on understanding GCA's causes, identifying patient groups, and optimizing therapies for better outcomes.
Area of Science:
- Rheumatology
- Internal Medicine
- Immunology
Background:
- Giant-cell arteritis (GCA) diagnosis and treatment have seen significant advancements.
- An aging population and improved diagnostic tools suggest an increasing prevalence of GCA.
- Unanswered questions remain regarding GCA pathogenesis and clinical heterogeneity.
Purpose of the Study:
- To outline a research agenda for advancing the understanding and management of GCA.
- To highlight key areas for future investigation in GCA research.
Main Methods:
- Review of current knowledge and identification of research gaps in GCA.
- Discussion of emerging trends in GCA diagnosis and treatment.
Main Results:
- Clarifying pathogenetic mechanisms and defining clinical subsets are crucial for improved GCA understanding.
- Optimizing imaging techniques, immunosuppressive therapies, and developing novel drugs are essential.
Conclusions:
- Future research must address GCA pathogenesis, clinical subsets, and therapeutic optimization.
- Personalized treatment strategies and understanding long-term outcomes are critical for managing GCA.
Related Concept Videos
01:26Atherosclerosis III: Management
47
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
47
01:26Aneurysm III: Interprofessional Care
34
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
34
01:11Genome-wide Association Studies-GWAS
14.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.4K